Back to top
more

TELA Bio (TELA)

(Delayed Data from NSDQ)

$4.45 USD

4.45
57,897

+0.06 (1.37%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $4.45 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?

Syros Pharmaceuticals (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates

TELA Bio (TELA) delivered earnings and revenue surprises of -20.45% and 2.09%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 8.62% and 174.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 23.26% and 45.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Surges 10.9%: Is This an Indication of Further Gains?

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of 20.69% and 0.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 15.38% and 21.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Roivant Sciences Ltd. (ROIV) Surges 8.9%: Is This an Indication of Further Gains?

Roivant Sciences Ltd. (ROIV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Strength Seen in TELA Bio, Inc. (TELA): Can Its 11.4% Jump Turn into More Strength?

TELA Bio, Inc. (TELA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

TELA Bio, Inc. (TELA) Reports Q1 Loss, Misses Revenue Estimates

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -23.53% and 2.39%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

SmileDirectClub (SDC) Reports Q1 Loss, Tops Revenue Estimates

SmileDirectClub (SDC) delivered earnings and revenue surprises of -14.29% and 9.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of 10.34% and 12.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 3.12% and 3.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio, Inc. (TELA) Reports Q3 Loss, Tops Revenue Estimates

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -12.28% and 4.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -146.67% and 121.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Surpasses Q3 Earnings and Revenue Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.50% and 1.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio, Inc. (TELA) Reports Q2 Loss, Tops Revenue Estimates

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -33.33% and 1.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 3.30% and 2.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 290.91% and 73.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

uniQure (QURE) Moves 27% Higher: Will This Strength Last?

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

TELA Bio, Inc. (TELA) Stock Jumps 6.6%: Will It Continue to Soar?

TELA Bio, Inc. (TELA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -50% and 4.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Reports Q1 Loss, Lags Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of 1.63% and 0.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Cytokinetics (CYTK): Can Its 11.5% Jump Turn into More Strength?

Cytokinetics (CYTK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -9.26% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?